Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 9/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079355 | 0.90 | PDGFRB (0.51) | PDGFRBPDGFRAADORA2ASYKLMNA | |
| SCHEMBL6777904 | 0.85 | PDGFRB (0.51) | PDGFRBPDGFRAEGFRFGFR1SYK | |
| SCHEMBL7200481 | 0.85 | PDGFRB (0.46) | PDGFRBPDGFRAEGFRFGFR1SYK | |
| SCHEMBL7081452 | 0.82 | SYK (0.50) | PDGFRBPDGFRASYKLMNAMAPK1 | |
| SCHEMBL7077421 | 0.82 | ROCK2 (0.55) | PDGFRBPDGFRAEGFRADORA2ASYK | |
| SCHEMBL7081454 | 0.80 | SYK (0.53) | EGFRFGFR1SYKLMNAMAPK1 | |
| SCHEMBL7082077 | 0.80 | SYK (0.52) | PDGFRBPDGFRASYKLMNAMAPK1 | |
| SCHEMBL7077410 | 0.80 | SYK (0.52) | SYKLMNAMAPK1KDRKDM4E | |
| SCHEMBL7083647 | 0.80 | SYK (0.48) | PDGFRBPDGFRASYKLMNAMAPK1 | |
| SCHEMBL7078467 | 0.80 | PDGFRB (0.56) | PDGFRBPDGFRASYKLMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | claimed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | claimed |
| US-6608058-B2 | Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-08-19 | — | — | US | disclosed |
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | DONG WHA PHARM. CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092709-A1 | 6-Methylnicotinamide derivatives as antiviral agents | TPMT, HAVCR2, NNMT | PDGFRB 3908/4885PDGFRA 3543/4885EGFR 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.